Miniatura

Fitxers

680389.pdf (4.7 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2018-04-12

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/135480

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1056/NEJMoa1801445

Resum

BACKGROUND Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B-cell-like [ABC], germinal-center B-cell-like [GCB], and unclassified) according to cell of origin that are associated with a differential response to chemotherapy and targeted agents. We sought to extend these findings by identifying genetic subtypes of DLBCL based on shared genomic abnormalities and to uncover therapeutic vulnerabilities based on tumor genetics. METHODS We studied 574 DLBCL biopsy samples using exome and transcriptome sequencing, array-based DNA copy-number analysis, and targeted amplicon resequencing of 372 genes to identify genes with recurrent aberrations. We developed and implemented an algorithm to discover genetic subtypes based on the co-occurrence of genetic alterations. RESULTS We identified four prominent genetic subtypes in DLBCL, termed MCD (based on the co-occurrence of MYD88L265P and CD79B mutations), BN2 (based on BCL6 fusions and NOTCH2 mutations), N1 (based on NOTCH1 mutations), and EZB (based on EZH2 mutations and BCL2 translocations). Genetic aberrations in multiple genes distinguished each genetic subtype from other DLBCLs. These subtypes differed phenotypically, as judged by differences in gene-expression signatures and responses to immunochemotherapy, with favorable survival in the BN2 and EZB subtypes and inferior outcomes in the MCD and N1 subtypes. Analysis of genetic pathways suggested that MCD and BN2 DLBCLs rely on "chronic active" B-cell receptor signaling that is amenable to therapeutic inhibition. CONCLUSIONS We uncovered genetic subtypes of DLBCL with distinct genotypic, epigenetic, and clinical characteristics, providing a potential nosology for precision-medicine strategies in DLBCL. (Funded by the Intramural Research Program of the National Institutes of Health and others.)

Matèries

Cèl·lules B, Limfomes, Genètica

Matèries (anglès)

B cells, Lymphomas, Genetics

Citació

Col·leccions

Articles publicats en revistes (Fonaments Clínics)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

SCHMITZ, Roland, WRIGHT, George w., HUANG, Da wei, JOHNSON, Calvin, PHELAN, James d., WANG, James q., ROULLAND, Sandrine, KASBEKAR, Monica, YOUNG, Ryan m, SHAFFER, Art, HODSON, Daniel j., XIAO, Wenming, YU, Xin, YANG, Yandan, ZHAO, Hong, XU, Weihong, LIU, Xuelu, ZHOU, Bin, DU, Wei, CHAN, Wing c., JAFFE, Elaine s., GASCOYNE, Randy d., CONNORS, Joseph m., CAMPO GÜERRI, Elias, LÓPEZ GUILLERMO, Armando, ROSENWALD, Andreas, OTT, German, DELABIE, Jan, RIMSZA, Lisa, TAY KUANG WEI, Kevin, ZELENETZ, Andrew d., LEONARD, John p., BARTLETT, Nancy l., TRAN, Bao, SHETTY, Jyoti, ZHAO, Yongmei, SOPPET, Dan r., PITTALUGA, Stefania, WILSON, Wyndham h., STAUDT, Louis m.. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. _New England Journal of Medicine_. 2018. Vol. 15, núm. 378, pàgs. 1396-1407. [consulta: 25 de gener de 2026]. ISSN: 0028-4793. [Disponible a: https://hdl.handle.net/2445/135480]

Exportar metadades

JSON - METS

Compartir registre